Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Hepatitis C AND Hepatitis C

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    757 result(s) found for: Chronic Hepatitis C AND Hepatitis C. Displaying page 38 of 38.
    «« First « Previous 30  31  32  33  34  35  36  37  38 
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004941-34 Sponsor Protocol Number: GFT505B-319-1 Start Date*: 2020-10-09
    Sponsor Name:IPSEN Pharma SAS
    Full Title: A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Ina...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10019805 - Hepatobiliary disorders 10034176 PBC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010582-23 Sponsor Protocol Number: CNTO148ART3002 Start Date*: 2010-01-04
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) SE (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001642-16 Sponsor Protocol Number: TAK-390MR_108 Start Date*: 2015-04-24
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 ...
    Medical condition: Acid-Related Disorders in Infants aged 1 to 11 months
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    17.1 100000004856 10000479 Acid reflux (oesophageal) LLT
    17.1 100000004856 10019326 Heartburn LLT
    17.1 100000004856 10063657 Erosive esophagitis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Temporarily Halted) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004444-38 Sponsor Protocol Number: GAIN/GEM/CIS Start Date*: 2019-01-11
    Sponsor Name:Krankenhaus Nordwest gGmbH
    Full Title: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally det...
    Medical condition: incidental gallbladder carcinoma (IGBC) or biliary tract cancer (BTC) (intrahepatic cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC))
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025734 Malignant neoplasm of biliary tract, part unspecified LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028982 Neoplasm biliary tract LLT
    20.0 10042613 - Surgical and medical procedures 10004675 Biliary tract and gallbladder therapeutic procedures HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017614 Gallbladder cancer PT
    21.1 10042613 - Surgical and medical procedures 10061962 Gallbladder operation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004601-17 Sponsor Protocol Number: 1508-GCG Start Date*: 2017-06-19
    Sponsor Name:European Organisation For Research and Treatment of Cancer (EORTC)
    Full Title: A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopi...
    Medical condition: Ovarian neoplasms
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051938 Ovarian adenocarcinoma LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-002324-32 Sponsor Protocol Number: I4V-MC-JADZ Start Date*: 2013-02-25
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who H...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) GB (Completed) PT (Completed) AT (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000177-25 Sponsor Protocol Number: ATA129-EBV-205 Start Date*: 2021-01-04
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
    Medical condition: • EBV+ primary imunodeficiency lymphoproliferative disease (LPD) • EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency • EBV+ post-transplant LPD involving the central nervous ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004247-29 Sponsor Protocol Number: AMD3100-EU23 Start Date*: 2007-08-22
    Sponsor Name:Genzyme Europe BV
    Full Title: A Multicenter, Randomized, Comparative, Patient-blinded Study to Evaluate the Safety and Efficacy of G-CSF Alone Versus AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Adult Patients w...
    Medical condition: Mobilization of stem cells prior to autologous stem cell transplantation in patients with multiple myeloma, non-Hodgkin's lympoma, and Hodgkin's disease.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10028228 Multiple myeloma LLT
    9.1 10020206 Hodgkin's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001476-11 Sponsor Protocol Number: AL002-2 Start Date*: 2020-11-12
    Sponsor Name:Alector Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
    Medical condition: Early Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006439-12 Sponsor Protocol Number: INSIGHT001:STARTDAIDSID#10619 Start Date*: 2009-05-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: Strategic Timing of AntiRetroviral Treatment(START)
    Medical condition: HIV Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) SE (Completed) PT (Completed) IE (Completed) EE (Completed) NO (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-001969-16 Sponsor Protocol Number: GS-US-183-0160 Start Date*: 2013-10-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10020192 HIV-1 LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-020992-21 Sponsor Protocol Number: AB06012 Start Date*: 2014-03-25
    Sponsor Name:AB Science
    Full Title: A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, Phase 2b/3 study to compare efficacy and safety of masitinib at 3 and 4.5 mg/kg...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000783-25 Sponsor Protocol Number: 0518-032 Start Date*: 2007-05-23
    Sponsor Name:Merck Sharp & Dohme de España, S.A.
    Full Title: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALE...
    Medical condition: HIV Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005127-34 Sponsor Protocol Number: 0518-018 Start Date*: 2006-03-14
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Opt...
    Medical condition: Unspecified human immuno-deficiency virus [HIV] disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020160 HIV disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002396-33 Sponsor Protocol Number: WA17044 Start Date*: 2005-12-27
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Estudio internacional, randomizado, doble ciego, para evaluar la eficacia y seguridad de diversos regímenes de retratamiento con rituximab en combinación con metotrexato, en pacientes con AR que ma...
    Medical condition: Artritis Reumatoide (Rheumatoid arthritis)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) FI (Completed) IT (Completed) GB (Completed) SK (Completed) HU (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2006-000864-94 Sponsor Protocol Number: EORTC protocol 10054 Start Date*: 2007-01-15
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A phase I-II study of lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer.
    Medical condition: Locally advanced/inflammatory or large operable brest cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 30  31  32  33  34  35  36  37  38 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 23:08:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA